Everand Logo

Welcome to Everand!

  • STAT

    STAT+: Pharmalittle: We’re reading about GLP-1 spending, biosimilar patient costs, and more

    Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
    by Ed Silverman Apr 24, 2024 1 minute
    Source: Alex Hogan/STAT

    Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is, after all, an accomplishment worth noting. And now, the next step is to forge ahead.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
    A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.

    Related Books & Audiobooks